Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice

Heart failure represents a primary cause of morbidity and mortality in older people and despite significant therapeutic advances, it is still characterized by important unmet needs, thus remaining a challenging field of clinical research. The recent PARADIGM-HF trial compared the novel compound LCZ6...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippatos, Gerasimos, Farmakis, Dimitrios, Parissis, John, Lekakis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334585/
https://www.ncbi.nlm.nih.gov/pubmed/25849438
http://dx.doi.org/10.1186/s12916-015-0272-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334585/
https://www.ncbi.nlm.nih.gov/pubmed/25849438
http://dx.doi.org/10.1186/s12916-015-0272-0

Ejemplares similares